Relmada Therapeutics, Inc. RLMD Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s investing cash flow?
- Relmada Therapeutics, Inc. (RLMD) reported investing cash flow of -$135.23M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Relmada Therapeutics, Inc.'s investing cash flow decreased by 980.4% year-over-year, from $15.36M to -$135.23M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s investing cash flow?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s investing cash flow has grown at a -2.9% compound annual growth rate (CAGR), from -$54.12M to -$48.14M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.